CAS 188627-80-7

Eptifibatida

Descripción:

Eptifibatida es un heptapéptido cíclico sintético que funciona como un potente agente antiplaquetario, utilizado principalmente en el manejo de síndromes coronarios agudos y durante intervenciones coronarias percutáneas. Actúa como un inhibidor reversible del receptor de glicoproteína IIb/IIIa en las plaquetas, evitando así la agregación plaquetaria y la formación de trombos. Eptifibatida se deriva del veneno de la serpiente de cascabel pigmea del sureste y se caracteriza por su afinidad de unión específica al receptor, que es crucial para la activación plaquetaria. La sustancia se administra típicamente por vía intravenosa y tiene una vida media relativamente corta, lo que requiere una infusión continua en entornos clínicos. Eptifibatida generalmente se tolera bien, aunque puede estar asociado con riesgos de sangrado, particularmente en pacientes con antecedentes de trastornos hemorrágicos o aquellos que se someten a procedimientos quirúrgicos. Su farmacocinética y farmacodinamia lo convierten en una herramienta valiosa en el cuidado cardiovascular agudo, contribuyendo a mejorar los resultados en pacientes de alto riesgo.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

InChI: InChI=1/C35H49N11O9S2/c36-31(52)26-17-57-56-12-10-27(47)43-22(7-3-4-11-39-35(37)38)32(53)41-16-28(48)44-25(14-29(49)50)34(55)45-24(13-18-15-40-20-6-2-1-5-19(18)20)30(51)21-8-9-23(42-21)33(54)46-26/h1-2,5-6,15,21-26,40,42H,3-4,7-14,16-17H2,(H2,36,52)(H,41,53)(H,43,47)(H,44,48)(H,45,55)(H,46,54)(H,49,50)(H4,37,38,39)/t21?,22-,23-,24-,25-,26-/m0/s1

SMILES: c1ccc2c(c1)c(C[C@H]1C(=O)C3CC[C@@H](C(=N[C@@H](CSSCCC(=N[C@@H](CCCCNC(=N)N)C(=NCC(=N[C@@H](CC(=O)O)C(=N1)O)O)O)O)C(=N)O)O)N3)c[nH]2

Sinónimos:

• [3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
• [(1S,4R,12S,18S,21S)-12-(4-carbamimidamidobutyl)-4-carbamoyl-21-(1H-indol-3-ylmethyl)-2,10,13,16,19,22-hexaoxo-6,7-dithia-3,11,14,17,20,26-hexaazabicyclo[21.2.1]hexacos-18-yl]acetic acid
• Map-Lys-Gly-Asp-Trp-Pro-Cys-Nh2
• Integrelin
• N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
• [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
• Eptifibatide Acetate

Eptifibatide

CAS: 188627-80-7

Eptifibatide, a RGD mimetic, is a glycoprotein (GP) IIb/IIIa receptor antagonist. Clinically, the peptide is used as an antiplatelet drug in combination with heparin and aspirin in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. CAS Number (eptifibatide acetate): 148031-34-9.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: ≥99%

Forma y color: White Lyophilisate

Peso molecular: 831.97

Ref: 01-4063191

Eptifibatide

CAS: 188627-80-7

Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Forma y color: White Powder

Peso molecular: 831.31561

Ref: 45-1238501

L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1→6)-disulfide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: 96%

Forma y color: Solid

Peso molecular: 831.9619

Ref: IN-DA001FDT

Eptifibatide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Peso molecular: 831.96

Ref: 7W-GP0493

Eptifibatide Acetate

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: 95%~99%

Forma y color: White to Off-white Powder

Peso molecular: 831.962

Ref: BP-BPPG027

Eptifibatide

CAS: 188627-80-7

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Peso molecular: 831.97

Ref: 4Z-PE-126001

Human Eptifibatide

CAS: 188627-80-7

Human Eptifibatide

Forma y color: White Lyophilised Powder

Peso molecular: 831.96g/mol

Ref: 54-BITP1545

Eptifibatide

Producto controlado

CAS: 188627-80-7

Applications An arginine-glycine-aspartate-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.
References Pathak, A., et al.: Cardiovas. Diabetol., 7 (2008), Hantgan, R., et al.: Biochem., 48, 8355 (2009), Giugliano, R., et al.: New Eng. J. Med., 360, 2176 (2009),

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Forma y color: Off White Solid

Peso molecular: 831.96

Ref: TR-E592000

Eptifibatide acetate

Producto controlado

CAS: 188627-80-7

Inhibits platelet glycoprotein IIb/IIIa receptors

Fórmula: C₃₅H₄₉N₁₁O₉S₂·xC₂H₄O₂

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 831.96 g/mol

Ref: 3D-FE40869

Eptifibatide

CAS: 188627-80-7

Eptifibatide is a drug that is used in the treatment of congestive heart failure, acute coronary syndrome and peripheral artery disease. It is a glycoprotein IIb/IIIa inhibitor that binds to integrin receptors on platelets and prevents them from binding to fibrinogen. This prevents blood clotting and reduces the risk of stroke or heart attack. Eptifibatide has been shown to be effective for the treatment of bowel disease, infectious diseases, and experimental models of myocardial infarcts. The drug has significant cytotoxicity, which may be due to its ability to inhibit cell proliferation by blocking protein synthesis at the ribosome level.
Eptifibatide has been shown to have a disulfide bond between two cysteine residues located in its amino-terminal region. This bond stabilizes the molecule in solution and ensures that it remains active until it reaches its target site.

Fórmula: C₃₅H₄₉N₁₁O₉S₂

Pureza: Min. 95%

Peso molecular: 831.98 g/mol

Ref: 3D-EPT-3786-PI